Desmopressin PRECAUTIONS, worldwide,supplier,Indian Industry,economy, Distributors, supplier, product, industry, portal Indian, raw material, manufacturer, provider, Desmopressin Monoacetate Cas No. 62288-83-9,

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

Desmopressin Monoacetate Taj Pharmaceuticals Ltd.

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Desmopressin Monoacetate Manufacturers in India Suppliers Desmopressin Monoacetate Exporters Distributors Desmopressin Monoacetate api active pharmaceuticals ingredients Desmopressin Monoacetate manufacturers Side Effects bulk drugs raw material Desmopressin Monoacetate companies Side Effects Importers Desmopressin Monoacetate Desmopressin Monoacetate Exporters Desmopressin Monoacetate exporters FDA Desmopressin Monoacetate DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Desmopressin Monoacetate manufacturing pharmaceutical drugs pharmaceutical intermediates Desmopressin Monoacetate pharmaceutical chemicals pharmaceutical raw materials Desmopressin Monoacetate active pharmaceutical ingredients Desmopressin Monoacetate committee active pharmaceutical ingredients manufacturer Desmopressin Monoacetate Active Pharmaceutical Ingredients manufacturer Desmopressin Monoacetate exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Desmopressin Monoacetate, Desmopressin Monoacetate manufacturer India, Desmopressin Monoacetate product, Desmopressin Monoacetate products, Api preparation, Certificate of Analysis API manufacturer product, Desmopressin Monoacetate anti ulcer product, Certificate of Origin COA Desmopressin Monoacetate COS Desmopressin Monoacetate, pharmaceutical generic, pharmaceutical drug, medical, Desmopressin Monoacetate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Desmopressin Monoacetate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Desmopressin Monoacetate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Desmopressin Monoacetate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Desmopressin Monoacetate ingredients, api, HIV Desmopressin Monoacetate, tablets, capsules, syrup & protein Desmopressin Monoacetate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Desmopressin Monoacetate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Desmopressin Monoacetate WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API >>>
	Pharmaceuticals API List
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

Desmopressin

HOME >> API >> API List1 >> Desmopressin Monoacetate >> Precautions

PRECAUTIONS
Desmopressin Monoacetate CAS Number 62288-83-9

Intranasal formulationsat high doses and Injection have infrequently produced a slight elevation of blood pressure which disappears with a reduction of dosage. Although this effect has not been observed when single oral doses up to 0.6 mg have been administered, the drug should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease, because of a possible rise in blood pressure.should be used with caution in patients with conditions associated with fluid and electrolyte imbalance, such as cystic fibrosis, heart failure and renal disorders because these patients are prone to hyponatremia.Rare severe allergic reactions have been reported

Nursing Mothers: There have been no controlled studies in nursing mothers. A single study in postpartum women demonstrated a marked change in plasma, but little if any change in assayablein breast milk following an intranasal dose of 0.01 mg.It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DDAVP is administered to nursing mothers.Pediatric Use: Central Diabetes Insipidus:have been used safely in pediatric patients, age 4 years and older, with diabetes insipidus for periods up to 44 months. In younger pediatric patients the dose must be individually adjusted in order to prevent an excessive decrease in plasma osmolality leading to hyponatremia and possible convulsions; dosing should start at 0.05 mg (1/2 of the 0.1 mg tablet). Use of in pediatric patients requires careful fluid intake restrictions to prevent possible hyponatremia and water intoxication. Fluid restriction should be discussed with the patient and/or guardian

Information Associated with Product:

DRUG DESCRIPTION

DOSAGE

SIDE EFFECTS

PRECAUTIONS >>

INTERACTION

PHARMALOGY

CONSUMER INFORMATION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj Pharmaceuticals API Logo

Api Manufacturing At Taj

Acamprosate Calcium	Clomipramine Hcl	Alendronate Sodium	Clonazepam	Amitriptyline	Clopidogrel Bisulfate	Anastrozole	Danazol	Atomoxetine Hcl	Desloratadine	Balsalazide
Desmopressin Monoacetate	Bicalutamide	Divalproex Sodium	Budesonide	Dobutamine Hcl	Bupropion Hcl	Donepezil	Calcitonin	Dothiepin Hcl	Capecitabine	Entacapone
Carbamazepine	Eptifibatide	Carboplatin	Escitalopram HBr	Carisoprodol	Eszopiclone	Carvedilol	Finasteride	Cefuroxime Axetil	Flurbiprofen	Cisplatin
Fluticasone Propionate	Citalopram Hbr	Fluvoxamine Maleate	Fosphenytoin Sodium

Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.